STAAR Surgical Reports Preliminary Net Sales For Q1 To Be In Excess Of $77M (Est $72.134M); Now Expects FY24 Net Sales Can Be At Higher End Of Prior Outlook Range Of $335M-$340M (Est $337.208M)

Author: Benzinga Newsdesk | April 04, 2024 07:11am

U.S. ICL sales expected to be $5 million for the quarter. This represents the Company's highest quarterly ICL sales in the U.S. since the Company obtained U.S. FDA approval of the EVO ICL in March 2022.  Cash, cash equivalents and investments available for sale was approximately $248 million and accounts receivable was approximately $70 million as of March 29, 2024, as compared to $232.4 million and $94.7 million, respectively, at December 29, 2023. The Company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.

Posted In: STAA